Last reviewed · How we verify

NCT06978426

Hand-Held Dynamometer Assessment: E-Sports Grip-Asymmetry Index as a Predictor of Wrist Pain

Recruiting now Last updated 18 May 2025
What this trial tests

trial testing Pain Group in Wrist Injuries in 56 participants. Currently enrolling.

Timeline
1 June 2025
Primary endpoint
1 December 2025
1 December 2025

Quick facts

Lead sponsorAhram Canadian University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment56
Start date1 June 2025
Primary completion1 December 2025
Estimated completion1 December 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ahram Canadian University

Who can join

Adults 18 to 30, any sex, with Wrist Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This cross-sectional study investigates whether a simple Grip-Asymmetry Index (GAI) can predict self-reported wrist pain in professional e-sports athletes. Professional gamers (aged 18-30) who play at least 35 hours per week will be assessed using a Jamar dynamometer to measure maximal grip force in both hands. The study will compare GAI between two groups: those with wrist pain (≥3/10 on Visual Analog Scale during play) and those without pain. A GAI cutoff value for predicting wrist pain risk will be established through ROC analysis, with additional factors such as gaming hours, BMI, and sex incorporated into a multivariable logistic regression model.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Wrist Injuries

Currently open trials in the same condition.

Other Ahram Canadian University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06978426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing